




Małgorzata Bobrowicz, MSc Department of Immunology Medical University of Warsaw Banacha 1a, 02-097 Warsaw, Poland

<u>Report from active participation in 55th American Society of Hematology</u> <u>Annual Meeting and Exposition,</u> <u>New Orleans, LO, USA, December 6-10, 2013 – Malgorzata Bobrowicz</u>

American Society of Hematology Annual Meeting and Exposition, held every year in the beginning of December, is the most important conference concerning novel trends in hematology therapy and research. This year's 55th ASH Meeting and Exposition in New Orleans gathered more than 20,000 participants – clinicians as well as scientists and corporate partners – from all over the world. During this meeting I had a pleasure to present our research during poster session *Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents*. This poster session was for me a great opportunity to share scientific ideas with other scientists and to establish contacts with pharmaceutical companies.



Title of the poster: HDAC6 Inhibition Increases CD20 Level and Improves The Efficacy Of Anti-CD20 Monoclonal Antibodies

Authors: <u>Malgorzata Bobrowicz (presenting author)</u>, Michal Dwojak, Kamil Bojarczuk, Magdalena Winiarska, Jakub Golab





In summary, we demonstrated, that HDAC6 inhibition in B-cell lymphoma cell lines and in samples from patients suffering from chronic lymphocytic leukemia (CLL) results in a significant increase in CD20 level which correlates with an improvement in the efficacy of rituximab. We showed for the first time that specific blocking of only one HDAC isoform – HDAC6 is sufficient to up-regulate CD20 level. What is more, our results reveal that HDAC6 inhibition leads to CD20 up-regulation in transcription-independent manner.